A Phase 2 Study of Safusidenib in People With Glioma

Full Title

A PHASE 3, MULTICENTER, CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB ERBUMINE IN PARTICIPANTS WITH ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA

Purpose

Researchers are seeking the best dose of safusidenib erbumine to treat glioma that came back or keeps growing after treatment. The people in this study have glioma with a mutation (change or variant) in a gene called IDH1. Many gliomas have IDH1 mutations, which help cancer cells survive and grow.

Safusidenib erbumine binds to and blocks certain mutated forms of the IDH1 protein. This blocking may help stop gliomas with the IDH1 mutation from growing, and it may also kill tumor cells. Safusidenib erbumine is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call the Brain Tumor Hotline at 866-886-9807. You may also call Dr. Thomas Kaley’s office at 212-639-5122.